Evaxion to Present Phase 2 Data on EVX-01 at ASCO 2024
COPENHAGEN, Denmark – Evaxion Biotech, a tech-biotech enterprise focusing on AI-driven immunology, has announced encouraging results from its ongoing Phase 2 clinical trial of EVX-01 at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluates the personalized cancer vaccine, EVX-01, in combination with anti-PD1 therapy for advanced melanoma patients. The ASCO Annual Meeting is scheduled from May 31 to June 4, 2024, in Chicago.
CEO Christian Kanstrup of Evaxion expressed optimism, noting that the immune responses generated by EVX-01 are both specific and robust. The company has observed booster immunizations further enhancing immune responses, suggesting a potential significant clinical benefit of the vaccine. Evaxion's AI-Immunology™ platform allows the precise selection of vaccine targets tailored to each patient's unique tumor and immune profile, representing a novel method to address considerable unmet medical needs.
The ongoing Phase 2 study builds on insights from the Phase 1 trial, corroborating the effectiveness of Evaxion’s AI-Immunology™ platform in selecting relevant therapeutic targets. Key findings from the Phase 2 study include:
1. EVX-01 induced clinically relevant immune responses in all assessed patients.
2. These responses were mediated by both CD4+ and CD8+ T-cells.
3. Booster immunizations appeared to enhance the immune response without raising safety concerns.
4. The EVX-01 vaccine was well-tolerated, with only mild adverse events reported.
The detailed study results will be presented by Senior Scientist Mads Lausen Nielsen on June 1, 2024, during the ASCO conference.
Details of the EVX-01 Phase 2 Clinical Trial
EVX-01, Evaxion’s leading clinical candidate, is a peptide-based personalized cancer vaccine. The Phase 2 clinical study is a self-sponsored, open-label, single-arm, multi-center trial conducted in collaboration with Merck Sharp & Dohme LLC, alongside principal investigators and research centers from Italy and Australia. The study aims to evaluate the efficacy and safety of EVX-01 in combination with pembrolizumab (KEYTRUDA®) in treatment-naive patients with metastatic or unresectable stage III or IV melanoma. More information is available under clinical trial ID NCT05309421.
About Evaxion Biotech
Evaxion Biotech A/S leverages its proprietary AI-Immunology™ platform to decode the human immune system and develop innovative immunotherapies for cancer, bacterial diseases, and viral infections. The company’s scalable AI prediction models are designed to create personalized vaccines and treatments tailored to individual immune landscapes. Evaxion combines advanced technology and immunology expertise to provide novel treatment options for patients with high unmet medical needs, aiming to transform lives with targeted therapies.
In summary, Evaxion Biotech's participation in the ASCO Annual Meeting underscores the potential of AI-driven personalized vaccines in cancer treatment. The promising results from the EVX-01 Phase 2 study, combined with the company's innovative use of artificial intelligence, highlight Evaxion's commitment to advancing personalized medicine and improving patient outcomes.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
